News >

FDA Grants Priority Review to Pemigatinib for FGFR2+ Cholangiocarcinoma

Gina Columbus @ginacolumbusonc
Published: Wednesday, Nov 27, 2019

Peter Langmuir, MD, group vice president, Targeted Therapies, Incyte

Peter Langmuir, MD

The FDA has granted a priority review to a new drug application (NDA) for pemigatinib as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements.1
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication